Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase 2 Study of Intravenous Bortezomib and Oral Panobinostat (LBH589) in Adult Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma After Failure of Conventional Chemotherapy

NCT00901147 is registered in ClinicalTrials.gov with Singapore General Hospital as lead sponsor.

NCT NCT00901147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00901147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase 2 Study of Intravenous Bortezomib and Oral Panobinostat (LBH589) in Adult Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma After Failure of Conventional Chemotherapy
Lead sponsor
Singapore General Hospital
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2009
Completion date
January 31, 2014
Enrollment
25 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic large cell lymphoma (alcl) (alk-1 negative), angioimmunoblastic t-cell lymphoma, enteropathy- type t-cell lymphoma, extranodal nk/t-cell lymphoma nasal type, hepatosplenic t-cell lymphoma, peripheral t-cell lymphoma (not otherwise specified), relapsed alcl (alk-1 positive) post autologous transplant